Patents by Inventor Rudolf Jaenisch

Rudolf Jaenisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200239855
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: October 28, 2019
    Publication date: July 30, 2020
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20200085817
    Abstract: Potassium chloride cotransporter-2 (KCC2) plays a critical role in brain function, and deficiency in KCC2 has been linked to neurological diseases, psychiatric disorders, and central nervous system injuries. In particular, Rett syndrome (RTT), a severe neurodevelopmental disorder caused by mutations in the X-linked gene Methyl CpG binding Protein 2 (MECP2), has been linked to deficits in KCC2. The disclosure reports the use of CRISPR/Cas9 genome-editing technology to generate stem cell-derived, genetically defined KCC2 reporter human neurons for large-scale compound screening. This screening platform has been utilized to identify a number of small molecule compounds that are capable of enhancing KCC2 expression in both wild-type and RTT neurons, as well as organotypical brain slices cultured from wild-type mice.
    Type: Application
    Filed: May 22, 2018
    Publication date: March 19, 2020
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Xin Tang
  • Publication number: 20200032292
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to chimeric animals comprising reprogrammed somatic cells of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Application
    Filed: June 11, 2019
    Publication date: January 30, 2020
    Inventors: Rudolf Jaenisch, Bryce Woodbury Carey
  • Publication number: 20190359959
    Abstract: The invention relates to methods of modifying DNA methylation by contacting a catalytically inactive site specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences.
    Type: Application
    Filed: August 18, 2017
    Publication date: November 28, 2019
    Inventors: Rudolf Jaenisch, X Shawn Liu, Hao Wu
  • Patent number: 10457917
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: October 29, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20190284537
    Abstract: The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.
    Type: Application
    Filed: February 19, 2019
    Publication date: September 19, 2019
    Inventors: Brett Chevalier, Alexander Marson, Richard A. Young, Ruth Foreman, Rudolf Jaenisch
  • Publication number: 20190241874
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 8, 2019
    Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
  • Publication number: 20190194764
    Abstract: In some aspects, described herein is a DNA methylation reporter. In some aspects, the DNA methylation reporter comprises a promoter whose activity can be affected by exogenous methylation changes without being independently regulated by the DNA methylation machinery, operably linked to a DNA sequence that encodes a reporter molecule. In some embodiments the DNA methylation reporter comprises (i) a promoter derived from a mammalian imprinted gene promoter; and (ii) a sequence that encodes a reporter molecule that is detectable in individual mammalian cells, wherein the promoter is operably linked to the sequence that encodes the reporter molecule. Also described are nucleic acids that comprise the DNA methylation reporter, cells that have the DNA methylation reporter integrated into their genome, and non-human mammals comprising cells that have the DNA methylation reporter integrated into their genome.
    Type: Application
    Filed: July 11, 2018
    Publication date: June 27, 2019
    Inventors: Yonatan Stelzer, Rudolf Jaenisch
  • Publication number: 20190078057
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: July 9, 2018
    Publication date: March 14, 2019
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Patent number: 10093904
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 9, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
  • Patent number: 10023922
    Abstract: In some aspects, described herein is a DNA methylation reporter. In some aspects, the DNA methylation reporter comprises a promoter whose activity can be affected by exogenous methylation changes without being independently regulated by the DNA methylation machinery, operably linked to a DNA sequence that encodes a reporter molecule. In some embodiments the DNA methylation reporter comprises (i) a promoter derived from a mammalian imprinted gene promoter; and (ii) a sequence that encodes a reporter molecule that is detectable in individual mammalian cells, wherein the promoter is operably linked to the sequence that encodes the reporter molecule. Also described are nucleic acids that comprise the DNA methylation reporter, cells that have the DNA methylation reporter integrated into their genome, and non-human mammals comprising cells that have the DNA methylation reporter integrated into their genome.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: July 17, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yonatan Stelzer, Rudolf Jaenisch
  • Patent number: 10017744
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: July 10, 2018
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20180179494
    Abstract: Described herein are cell culture media useful for the differentiation of human pluripotent stem cells into microglia. The methods described herein relate to in vitro generation of expandable, bankable, microglial cells by directed differentiation from human pluripotent stem cells (induced or embryonic). Using only defined cell culture media, differentiation of pluripotent stem cells is directed down a mesodermal path, in a rapid and scalable fashion, to generate cells adopting signatures of their in vivo counterparts, including gene expression, protein marker expression and functionality.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 28, 2018
    Inventors: Julien MUFFAT, Yun LI, Rudolf JAENISCH
  • Patent number: 9834787
    Abstract: Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: December 5, 2017
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Dirk Hockemeyer, Michael C. Holmes, Rudolf Jaenisch, Frank Soldner, Fyodor Urnov, Shuyuan Yao
  • Publication number: 20170342386
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
  • Publication number: 20170240865
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20170218341
    Abstract: The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.
    Type: Application
    Filed: February 9, 2017
    Publication date: August 3, 2017
    Inventors: Brett Chevalier, Alexander Marson, Richard A. Young, Ruth Foreman, Rudolf Jaenisch
  • Patent number: 9714414
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: July 25, 2017
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
  • Patent number: 9670464
    Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 6, 2017
    Assignee: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Rudolf Jaenisch, Konrad Hochedlinger
  • Publication number: 20170114323
    Abstract: The present disclosure provides compounds of any one of Formulae (A) to (L). The present disclosure also provides compositions, uses, and methods that include or involve a compound described herein, a serine/threonine-protein kinase B-Raf (BRAF) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a vascular endothelial growth factor 1 (VEGFR1) inhibitor, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, or a combination thereof. The compounds, compositions, uses, and methods are useful in changing the pluripotency state of a vertebrate cell to a more naive state.
    Type: Application
    Filed: June 19, 2015
    Publication date: April 27, 2017
    Applicants: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Thorold W. Theunissen, Nathanael S. Gray, Rudolf Jaenisch